Hinchcliff E, et al. - Researchers examined 44 women who received an immune checkpoint inhibitor for recurrent ovarian cancer between January 2012 and August 2017 to study the clinical outcomes. Disease status was determined using RECIST criteria. Trial protocols were used to grade the immune related adverse events (irAE). They documented a response rate that was similar to prior literature. Also, a correlation of platinum sensitivity at time of checkpoint inhibitor initiation with response was seen in patients with high grade serous (HGSOC) pathology. Ovarian cancer patients more commonly exhibited grade 3/4 hepatic and pancreatic enzyme elevations vs what has been previously reported in other tumor types. There was an inverse correlation of the number of genes mutated to risk of this type of irAEs but not to total irAEs.